Skip to main content
SpringerLink
Log in

Allogene hämatopoetische Stammzelltransplantation

Eine Option bei Autoimmunerkrankungen?

Allogeneic stem cell transplantation

An option for autoimmune diseases?

  • Leitthema
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Nach der tierexperimentellen Evidenz und den Erfahrungen von Patienten, die eine koexistente Autoimmunerkrankung haben, hat die allogene hämatopoetische Stammzelltransplantation das Potenzial immunologische Toleranz zu etablieren und zu erhalten. Andererseits ist sie mit einer hohen behandlungsbedingten Sterblichkeit assoziiert und kann durch die Transplantat-gegen-Wirt-Reaktion vielfältige immunologische Erkrankungen verursachen. Sie ist mit Ausnahme der schweren aplastischen Anämie keine etablierte Therapie von Autoimmunerkrankungen, wird in Studien untersucht und kann bei schweren refraktären Immunzytopenien erwogen werden.

Abstract

According to experimental animal models and experiences of patients with coexisting autoimmune diseases, allogeneic stem cell transplantation has the potential to reestablish and maintain immunological tolerance. On the other hand, it is associated with significant treatment related mortality and may induce diverse immunological diseases by graft-versus-host reaction. Other than with severe aplastic anemia, it is not an established therapy for autoimmune diseases; it is under investigation in clinical trials and might be considered in severe, refractory immune cytopenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Arai S, Arora M, Wang T et al (2015) Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 21:266–274

    Article  PubMed  Google Scholar 

  2. Bornhäuser M, Aringer M, Thiede C (2010) Mixed lymphohematopoietic chimerism and response in Wegener’s granulomatosis. N Engl J Med 362:2431–2432

    Article  PubMed  Google Scholar 

  3. Burt RK, Oyama Y, Verda L et al (2004) Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism. Arthritis Rheum 50:2466–2470

    Article  PubMed  Google Scholar 

  4. Daikeler T, Hügle T, Farge D et al (2009) Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant 44:27–33

    Article  CAS  PubMed  Google Scholar 

  5. Daikeler T, Labopin M, Di Gioia M et al (2011) Secondary autoimmune diseases occurring after HSZT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood 118:1693–1698

    Article  CAS  PubMed  Google Scholar 

  6. Griffith LM, Pavletic SZ, Tyndall A et al (2005) Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant 11:862–870

    Article  PubMed  Google Scholar 

  7. Griffith LM, Pavletic SZ, Tyndall A et al (2006) Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases – a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapy. Biol Blood Marrow Transplant 12:688–690

    Article  PubMed  Google Scholar 

  8. Hinterberger W, Hinterberger-Fischer M, Marmont A (2002) Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant 30:753–759

    Article  CAS  PubMed  Google Scholar 

  9. Holbro A, Abinun M, Daikeler T (2012) Management of autoimmune diseases after haematopoietic stem cell transplantation. Br J Haematol 157:281–290

    Article  CAS  PubMed  Google Scholar 

  10. Ikehara S, Good RA, Nakamura T et al (1985) Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci USA 82:2483–2487

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Khorshid O, Hosing C, Bibawi S et al (2004) Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J Rheumatol 31:2513–2516

    PubMed  Google Scholar 

  12. Kojima R, Kami M, Kim S‑W et al (2003) Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 32:439–442

    Article  CAS  PubMed  Google Scholar 

  13. Loh Y, Oyama Y, Statkute L et al (2007) Non-myeloablative allogeneic hematopoietic stem cell transplantation for severe systemic sclerosis: graft-versus-autoimmunity without graft-versus-host disease? Bone Marrow Transplant 39:435–437

    Article  CAS  PubMed  Google Scholar 

  14. Lopez-Cubero SO, Sullivan KM, Mcdonald GB (1998) Course of Crohn’s disease after allogeneic marrow transplantation. Gastroenterology 114:433–440

    Article  CAS  PubMed  Google Scholar 

  15. Marmont AM (2004) Stem cell transplantation for autoimmune disorders. Coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Haematol 17:223–232

    Article  PubMed  Google Scholar 

  16. Marmont AM, Dominietto A, Gualandi F et al (2006) Pure white cell aplasia (PWCA) relapsing after allogeneic BMT and successfully treated with nine DLIs. Biol Blood Marrow Transplant 12:987–989

    Article  CAS  PubMed  Google Scholar 

  17. Mcallister LD, Beatty PG, Rose J (1997) Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant 19:395–397

    Article  CAS  PubMed  Google Scholar 

  18. Morton JI, Siegel BV (1974) Transplantation of autoimmune potential. I. Development of antinuclear antibodies in H‑2 histocompatible recipients of bone marrow from New Zealand black mice. Proc Natl Acad Sci USA 71:2162–2165

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Nelson JL, Torrez R, Louie FM et al (1997) Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol Suppl 48:23–29

    CAS  PubMed  Google Scholar 

  20. Pasquini MC, Voltarelli J, Atkins HL et al (2012) Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 18:1471–1478

    Article  PubMed  PubMed Central  Google Scholar 

  21. Rabusin M, Snowden JA, Veys P et al (2013) Long-term outcomes of hematopoietic stem cell transplantation for severe treatment-resistant autoimmune cytopenia in children. Biol Blood Marrow Transplant 19:666–669

    Article  PubMed  Google Scholar 

  22. Scheinberg P, Young NS (2012) How I treat acquired aplastic anemia. Blood 120:1185–1196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Slavin S, Nagler A, Varadi G et al (2000) Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 28:853–857

    Article  CAS  PubMed  Google Scholar 

  24. Snowden JA, Pearce RM, Lee J et al (2012) Haematopoietic stem cell transplantation (HSZT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997–2009. Br J Haematol 157:742–746

    Article  PubMed  Google Scholar 

  25. Snowden JA, Saccardi R, Allez M et al (2012) Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 47:770–790

    Article  CAS  PubMed  Google Scholar 

  26. Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912–2919

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Stavenga M, Leavis HL, De Witte TM et al (2016) Allogeneic stem cell transplantation in a patient with myelodysplastic syndrome and polyarteritis nodosa: a case report and systematic review. Ann Hematol 95:645–647

    Article  PubMed  Google Scholar 

  28. Sureda A, Bader P, Cesaro S et al (2015) Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 50:1037–1056

    Article  CAS  PubMed  Google Scholar 

  29. Tapprich C, Fenk R, Schneider P et al (2003) Early recurrence of rheumatoid arthritis after nonmyeloablative allogeneic blood stem cell transplantation in a patient with multiple myeloma. Bone Marrow Transplant 32:629–631

    Article  CAS  PubMed  Google Scholar 

  30. Thomas ED (1997) Pros and cons of stem cell transplantation for autoimmune disease. J Rheumatol Suppl 48:100–102

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Onkologie, Hämatologie, klinische Immunologie, Rheumatologie, Pulmologie, Medizinische Klinik der Universität Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Deutschland

    S. Wirths, W. Bethge & J. C. Henes

Authors
  1. S. Wirths
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Bethge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. C. Henes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Wirths.

Ethics declarations

Interessenkonflikt

S. Wirths, W. Bethge und J. C. Henes geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

J. Henes, Tübingen

I. Kötter, Hamburg

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wirths, S., Bethge, W. & Henes, J.C. Allogene hämatopoetische Stammzelltransplantation. Z Rheumatol 75, 780–785 (2016). https://doi.org/10.1007/s00393-016-0194-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-016-0194-z

Schlüsselwörter

Keywords

Search

Navigation